Clinical Trial

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Protocol Amendment History 1 change
notable Primary completion moved earlier: 2026-12-31 -> 2026-06-23 2026-07-30
Trial Details
NCT Number NCT03785249
Lead Sponsor Mirati Therapeutics Inc.
Conditions Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Enrollment 731 participants
Start Date 2019-01-15
Primary Completion 2026-06-23 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-29